Efficacy of dacomitinib in patients with non-small cell lung cancer carrying complex EGFR mutations: a real-world study

BACKGROUND: Dacomitinib is a first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring common epidermal growth factor receptor (EGFR) mutations; however, clinical evidence of its activity on NSCLC with complex EGFR mutations is limited. METHODS: Patients harboring complex (...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hong-Shuai, Li, Jun-Ling, Yan, Xiang, Xu, Hai-Yan, Zhou, Li-Qiang, Hu, Xing-Sheng, Wang, Yu-Ying, Lei, Si-Yu, Wang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186228/
https://www.ncbi.nlm.nih.gov/pubmed/35693621
http://dx.doi.org/10.21037/jtd-21-1841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186228/
https://www.ncbi.nlm.nih.gov/pubmed/35693621
http://dx.doi.org/10.21037/jtd-21-1841

Ejemplares similares